CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.88B, above the global median of $1.15B
- PositionProfit margin is 44.1%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
6.77TKRW4.88B · vs all stocks (USD)
Trailing P/E
25.37xvs Biotechnology peers
Revenue (TTM)
790.25BKRW569.42M · vs all stocks (USD)
Profit Margin
44.14%vs Biotechnology peers
Beta
0.7280xvs all stocks
52-Week Change
-11.01%vs all stocks
Market Capitalization
6.77TKRW4.88B · vs all stocks (USD)
Enterprise Value
6.58TKRW4.74B · vs all stocks (USD)
Trailing P/E
25.37xvs Biotechnology peers
Forward P/E
16.51xvs Biotechnology peers
PEG Ratio
0.0724xvs Biotechnology peers
Price to Sales (TTM)
8.47xvs Biotechnology peers
Price to Book (MRQ)
7.27xvs Biotechnology peers
Enterprise to Revenue
8.32xvs Biotechnology peers
Enterprise to EBITDA
23.13xvs Biotechnology peers
Gross Margin
93.71%vs Biotechnology peers
Profit Margin
44.14%vs Biotechnology peers
Operating Margin
39.39%vs Biotechnology peers
Return on Assets (TTM)
14.43%vs Biotechnology peers
Return on Equity (TTM)
44.16%vs Biotechnology peers
Revenue (TTM)
790.25BKRW569.42M · vs all stocks (USD)
Revenue per Share (TTM)
10.09KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
57.80%vs Biotechnology peers
Gross Profit (TTM)
743.51BKRW535.75M · vs all stocks (USD)
EBITDA (TTM)
265.09BKRW191.01M · vs all stocks (USD)
Net Income (TTM)
348.81BKRW251.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
351.30%vs Biotechnology peers
Operating Cash Flow (TTM)
166.97BKRW120.31M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
75.88BKRW54.68M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
13.23BKRWFY2025 · Dec 31, 2025Revenue
706.74BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
42.90BKRWFY2025 · Dec 31, 2025Gross Profit
663.84BKRWFY2025 · Dec 31, 2025Operating Income
203.94BKRW146.95M · vs all stocks (USD)
Pre-tax Income
150.88BKRWFY2025 · Dec 31, 2025Income Tax Expense
-102.37BKRWFY2025 · Dec 31, 2025Net Income
253.25BKRWFY2025 · Dec 31, 2025EBIT
158.57BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
183.33BKRWFY2025 · Dec 31, 2025Research & Development
174.34BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
146.29BKRWFY2025 · Dec 31, 2025Other Operating Expenses
5.81BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
7.08BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
7.69BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
253.25BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
13.70BKRWFY2025 · Dec 31, 2025Operating Cash Flow
186.49BKRWFY2025 · Dec 31, 2025Free Cash Flow
179.60BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
307.77BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
253.25BKRWFY2025 · Dec 31, 2025Stock-based Compensation
3.63BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-27.94BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-58.40BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
15.94BKRWFY2025 · Dec 31, 2025Capital Expenditures
-6.89BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-22.12BKRWFY2025 · Dec 31, 2025Purchase of Investments
-4.61BKRWFY2025 · Dec 31, 2025Sale of Investments
239.46MKRWFY2025 · Dec 31, 2025Other Investing Activity
-2.07BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.33BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-150.72BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-150.72BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-301.44BKRWFY2025 · Dec 31, 2025Shares Outstanding
78.31MSharesUpdated Aug 20, 2026Float Shares
39.02MSharesUpdated Aug 20, 2026% Held by Insiders
50.17%vs all stocks
% Held by Institutions
12.27%vs all stocks
Total Cash (MRQ)
310.86BKRW223.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.97KKRWUpdated Aug 20, 2026Total Debt (MRQ)
49.98BKRW36.01M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0536xvs Biotechnology peers
Current Ratio (MRQ)
2.49xvs Biotechnology peers
Book Value per Share (MRQ)
11.90KKRWUpdated Aug 20, 2026Total Assets
1.20TKRW863.45M · vs all stocks (USD)
Total Current Assets
683.23BKRWFY2025 · Dec 31, 2025Total Liabilities
372.04BKRWFY2025 · Dec 31, 2025Total Non-current Assets
515.08BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
76.84BKRWFY2025 · Dec 31, 2025Total Current Liabilities
295.20BKRWFY2025 · Dec 31, 2025Cash Equivalents
307.77BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
307.77BKRWFY2025 · Dec 31, 2025Other Short-term Investments
1.71BKRWFY2025 · Dec 31, 2025Accounts Receivable
228.83BKRWFY2025 · Dec 31, 2025Inventory
100.24BKRWFY2025 · Dec 31, 2025Accounts Payable
9.34BKRWFY2025 · Dec 31, 2025Short-term Debt
8.43BKRWFY2025 · Dec 31, 2025Other Current Liabilities
41.89BKRWFY2025 · Dec 31, 2025Long-term Debt
40.49BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
15.37BKRWFY2025 · Dec 31, 2025Common Stock (Book)
39.16BKRWFY2025 · Dec 31, 2025Retained Earnings
-354.14BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
826.27BKRW595.38M · vs all stocks (USD)
52-Week Low
73.00KKRWUpdated Aug 20, 202652-Week High
144.10KKRWUpdated Aug 20, 202652-Week Change
-11.01%vs all stocks
Beta
0.7280xvs all stocks
50-Day MA
83.90KKRWUpdated Aug 20, 2026200-Day MA
105.26KKRWUpdated Aug 20, 2026Avg 10-Day Volume
136.40KSharesUpdated Aug 20, 2026Avg 30-Day Volume
126.85KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
3.41KKRWUpdated Aug 20, 202612 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 44.1%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.44Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 44.2%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.44Industry median: -0.22Industry P95: 0.23Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 251,337,012.423Operating Cash Flow (USD, TTM): 120,308,608.961
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.50
Altman Z-Score 11.93: safe zoneNotable
Altman Z-Score: 11.93
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.88B, above the global median of $1.15BNotable
Market cap (USD): 4,881,142,703.83Global Median: 1,146,734,693.424
Revenue is $569.42M, above the global median of $520.53MNotable
Revenue (USD): 569,422,348.435Global Median: 520,528,949.311
Levered free cash flow is $54.68M, above the global median of $16.24MNotable
Levered free cash flow (USD): 54,675,506.575Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ajanta Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Keeper Technical Laboratory
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Novo Nordisk A/S
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated